Who is Mavacamten treatment intended for?
Mavacamten is indicated for adult patients with hypertrophic obstructive cardiomyopathy who are at least 18 years of age and meet certain clinical criteria established by the Italian Medicines Agency. The AIFA has precisely identified the drug's prescribability and reimbursement requirements.
Prescriptions and reimbursement: what the National Health Service provides
The drug is covered by the National Health ServiceReimbursement means that the drug will be dispensed at no direct cost to patients who meet the established criteria.
The role of the Regions and prescribing centers
The individual Regions have identified, or are in the process of identifying and/or accrediting specialist centers authorized to prescribe the drug, according to the criteria established by AIFA.
The list of authorized centers on the AICARM website
The list updated list of prescribing centers identified on the national territory, Organized region by region, it is now available on the Association's website, and offers patients a practical tool for locating the nearest referral facility. The territorial distribution is still uneven.
To view the updated list, available in the new New Drugs section of our website, open the following link: List of Mavacamten prescription centers.
The updated list of prescribing centers already operating throughout the country, organized by region, is now available on the Association's website, offering patients a practical tool for locating the nearest referral facility.
How to access the specialist assessment
The patients concerned, both those already in charge and those who need an initial evaluation, must contact the cardiology departments of the hospitals indicated in the list and, where applicable, to the specific Cardiomyopathy Unit. Here, they will receive a specialist assessment that will determine their eligibility for treatment according to the parameters established by AIFA.
A constantly updated list
The list published by AICARM will be updated periodically To list the new centers that will receive authorization. The centers currently listed represent only the first to be authorized, and the number is expected to grow progressively as the service expands nationwide.
